Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1983 1
1984 3
1985 1
1986 2
1987 2
1988 2
1989 6
1990 5
1991 4
1992 2
1993 1
1994 4
1996 1
1997 5
1998 4
2000 3
2001 4
2002 8
2003 2
2004 5
2005 12
2006 7
2007 6
2008 4
2009 8
2010 8
2011 7
2012 7
2013 9
2014 8
2015 11
2016 7
2017 7
2018 7
2019 13
2020 12
2021 17
2022 10
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Results by year

Filters applied: . Clear all
Page 1
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Pascual J, et al. Among authors: citterio f. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. J Am Soc Nephrol. 2018. PMID: 29752413 Free PMC article. Clinical Trial.
Response.
Citterio F. Citterio F. Transplant Proc. 2015 Jul-Aug;47(6):2075. doi: 10.1016/j.transproceed.2015.07.009. Transplant Proc. 2015. PMID: 26293101 No abstract available.
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J; TRANSFORM investigators. Berger SP, et al. Among authors: citterio f. Am J Transplant. 2019 Nov;19(11):3018-3034. doi: 10.1111/ajt.15480. Epub 2019 Jul 1. Am J Transplant. 2019. PMID: 31152476 Free article. Clinical Trial.
Preface.
Citterio F, Berloco P. Citterio F, et al. Transplant Proc. 2017 May;49(4):621. doi: 10.1016/j.transproceed.2017.02.042. Transplant Proc. 2017. PMID: 28457358 No abstract available.
Thymoglobuline plus basiliximab a mixed cocktail to start?
Spagnoletti G, Salerno MP, Calia R, Romagnoli J, Citterio F. Spagnoletti G, et al. Among authors: citterio f. Transpl Immunol. 2017 Aug;43-44:1-2. doi: 10.1016/j.trim.2017.06.005. Epub 2017 Jul 1. Transpl Immunol. 2017. PMID: 28676335
Anonymity and live-donor transplantation: an ELPAT view.
Mamode N, Lennerling A, Citterio F, Massey E, Van Assche K, Sterckx S, Frunza M, Jung H, Pascalev A, Zuidema W, Johnson R, Loven C, Weimar W, Dor FJ. Mamode N, et al. Among authors: citterio f. Transplantation. 2013 Feb 27;95(4):536-41. doi: 10.1097/TP.0b013e31827e31f7. Transplantation. 2013. PMID: 23334435 Review.
Belatacept utilization recommendations: an expert position.
Grinyó JM, Budde K, Citterio F, Charpentier B. Grinyó JM, et al. Among authors: citterio f. Expert Opin Drug Saf. 2013 Jan;12(1):111-22. doi: 10.1517/14740338.2013.748747. Epub 2012 Dec 4. Expert Opin Drug Saf. 2013. PMID: 23206310 Review.
Global Kidney Exchange: opportunity or exploitation? An ELPAT/ESOT appraisal.
Ambagtsheer F, Haase-Kromwijk B, Dor FJMF, Moorlock G, Citterio F, Berney T, Massey EK. Ambagtsheer F, et al. Among authors: citterio f. Transpl Int. 2020 Sep;33(9):989-998. doi: 10.1111/tri.13630. Epub 2020 May 20. Transpl Int. 2020. PMID: 32349176 Free PMC article. Review.
219 results